Abstract

BackgroundInjections of lipopolysaccharide in animal models generate acute anterior uveitis (also known as endotoxin-induced uveitis), but the effects of lipopolysaccharide injection are unknown in humans. We describe an unusual case in which acute anterior uveitis was dramatically activated subsequent to botulinum toxin injection in a patient with Behçet’s disease but the acute anterior uveitis was satisfactorily attenuated by infliximab.Case presentationA 53-year-old Japanese man had normal ocular findings at his regularly scheduled appointment. He had been diagnosed as having incomplete-type Behçet’s disease 11 years before. Three years after the diagnosis he was given systemic infusions of 5 mg/kg infliximab every 8 weeks and he had not experienced a uveitis attack for 8 years with no treatment other than infliximab. Two days after the eye examination, he received intracutaneous botulinum toxin injections to treat axillary hyperhidrosis on both sides. Three hours after the injections, he noted rapidly increasing floaters in his right eye. Four days after the injections, his right eye showed severe acute anterior uveitis with deteriorated aqueous flare and anterior vitreous opacity. He received his scheduled infliximab injection, and the right acute anterior uveitis immediately attenuated.ConclusionsBotulinum toxin may have clinical effects similar to those of lipopolysaccharide in endotoxin-induced uveitis models. To the best of our knowledge, this is the first report to suggest that botulinum toxin may trigger acute anterior uveitis, although the precise mechanism is still unclear.

Highlights

  • Injections of lipopolysaccharide in animal models generate acute anterior uveitis, but the effects of lipopolysaccharide injection are unknown in humans

  • To the best of our knowledge, this is the first report to suggest that botulinum toxin may trigger acute anterior uveitis, the precise mechanism is still unclear

  • In animal models, systemic and local injection of lipopolysaccharide (LPS) induces acute anterior uveitis (AAU), which is known as endotoxin-induced uveitis (EIU)

Read more

Summary

Conclusions

We report an unusual case in which subcutaneous injections of botulinum toxin to treat axillary hyperhidrosis appeared to trigger AAU in a patient with BD even though he had not experienced a uveitis attack since starting periodic infliximab treatment 8 years ago. He received his regularly scheduled infliximab injection 2 days later, and the AAU resolved quickly with near-normal opacity, intraocular pressure, and LF a month later. To the best of our knowledge, this is the first report of the triggering of AAU by botulinum toxin and effective attenuation of AAU by infliximab in a patient with BD

Background
Discussion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.